Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
+$0.11 today
- Market cap
- $193.04M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
Volume 0.27M
Average 0.31M
Returns on capital
Precision BioSciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-50.5%
avg -75.5%
ROIC
-35.5%
avg -37.2%
ROA
-30.2%
avg -30.7%
Analysis
ROA is currently the strongest return metric at -30.2% versus its period average of -30.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael Amoroso | President, Chief Executive Officer & Director | USD 1.16M | 48 | 243.39K | 1.90% |
John Alexander Kelly | Chief Operating Officer | USD 717.06K | 59 | 125.88K | 0.98% |
Dario Scimeca | Chief Legal Officer & Secretary | USD 659.64K | 51 | 56.78K | 0.44% |
Jefferson J. Smith | Co-Founder & Chief Research Officer | USD 640.2K | 53 | 121.93K | 0.95% |
Naresh Tanna | Chief Financial Officer | USD 623.58K | 45 | — | — |
Cindy Atwell | Chief Development Officer | — | — | — | — |
Mei Burris | VP of Finance & Chief Accounting Officer | — | 40 | — | — |
Cassie Gorsuch | Chief Scientific Officer | — | — | — | — |
Neil Leatherbury | Senior Vice President and Head of Chemistry, Manufacturing & Controls | — | — | — | — |
Juli Blanche | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$63,214.54
Sells
9
$458,775.31
Net Transaction Value
−$395,560.77
Net selling
Most Active
Scimeca Dario
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | Scimeca Dario Direct | Sell | $27.5K$27,504.75 |
| Sep 28, 26Sep 28, 2026 | Frankel Stanley Direct | Buy | $6K$6,000.00 |
| Sep 25, 26Sep 25, 2026 | Brown Melinda Direct | Buy | $7.1K$7,116.45 |
| Sep 25, 26Sep 25, 2026 | Germano Geno J Direct | Buy | $16.4K$16,384.52 |
| Feb 18, 26Feb 18, 2026 | Kelly John Alexander Direct | Sell | $31.3K$31,292.16 |
| Feb 18, 26Feb 18, 2026 | Amoroso Michael Direct | Sell | $78.9K$78,946.56 |
| Feb 18, 26Feb 18, 2026 | SMITH J. JEFFERSON Direct | Sell | $18.9K$18,912.00 |
| Feb 18, 26Feb 18, 2026 | Scimeca Dario Direct | Sell | $18.9K$18,912.00 |
| Jan 22, 26Jan 22, 2026 | Amoroso Michael Direct | Sell | $145.1K$145,111.83 |
| Jan 21, 26Jan 21, 2026 | Kelly John Alexander Direct | Sell | $61.3K$61,308.39 |
1–10 of 15
Summary
Insiders reported 6 buys worth $63,214.54 and 9 sells worth $458,775.31 over the last 12 months. That adds up to net selling of $395,560.77. Scimeca Dario was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +10.9% | +33.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +10.9% over three years. Forward estimates point to Revenue at +33.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Precision BioSciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DTIL's management, answered from reported figures.
Who manages DTIL?
Precision BioSciences, Inc. (DTIL) lists 10 active executives. The top listed executive is Dario Scimeca, Chief Legal Officer & Secretary.
Are DTIL insiders buying or selling?
Recent insider activity shows net selling of $422,709.84.
Continue the stock analysis
Jump to another research area for this company.